Richard Bernstein Advisors LLC Has $1.32 Million Position in Amgen Inc. $AMGN

Richard Bernstein Advisors LLC trimmed its stake in Amgen Inc. (NASDAQ:AMGN) by 64.9% in the third quarter, HoldingsChannel reports. The firm owned 4,674 shares of the medical research company’s stock after selling 8,655 shares during the period. Richard Bernstein Advisors LLC’s holdings in Amgen were worth $1,319,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. West Family Investments Inc. boosted its position in shares of Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after purchasing an additional 30 shares in the last quarter. Viawealth LLC grew its stake in shares of Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after buying an additional 30 shares during the period. LOM Asset Management Ltd increased its position in Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after buying an additional 30 shares in the last quarter. TAGStone Capital Inc. increased its position in Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after buying an additional 32 shares in the last quarter. Finally, BBR Partners LLC raised its stake in Amgen by 0.5% during the 3rd quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after buying an additional 32 shares during the period. 76.50% of the stock is owned by institutional investors.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Pipeline and capital returns: Coverage highlights Amgen’s oncology progress and frames the company’s dividend and buyback profile as supportive of long‑term growth and income, which underpins investor confidence in cash flow stability. Amgen Oncology Advances Test Dividend Strength And Long Term Growth Story
• Positive Sentiment: Industry endorsement: CNBC commentary cites Amgen as one of the larger biotech names that could be resilient amid structural changes (e.g., limited disruption from AI), which supports defensive large‑cap biotech demand. Biotech is resistant to AI disruption. Josh Brown likes these two stocks in the industry
• Positive Sentiment: Analyst/investor idea coverage: Earnings and strategy coverage from outlets like Zacks flag Amgen as a portfolio pick under their approach, reinforcing interest from strategy-driven investors. Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus
• Neutral Sentiment: Short‑interest reporting appears anomalous: Data feeds show a reported increase in short interest but list zero shares/NaN values, suggesting the spike is likely a reporting glitch rather than confirmed bearish positioning. Monitor for corrected filings. (No direct article link—data entry reported.)
• Negative Sentiment: Analyst move: Jefferies initiated coverage on AMGN with a Hold rating and a $350 price target, signaling limited upside from current levels and contributing to downward pressure on the stock. Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence
• Negative Sentiment: Policy risk: A newly introduced bill (H.R. 7871) to codify Medicaid value‑based purchasing could change how discounts/rebates and outcomes‑based payments are calculated and reported. That framework may reduce realized prices or increase rebate liabilities for manufacturers that enter VBP arrangements—a potential long‑term headwind for Amgen’s pricing and margins in Medicaid. New Bill: Representative Brett Guthrie introduces H.R. 7871: Medicaid VBPs for Patients Act

Amgen Price Performance

Shares of Amgen stock opened at $375.43 on Wednesday. The business has a 50 day moving average of $355.15 and a 200 day moving average of $323.95. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a market cap of $202.38 billion, a PE ratio of 26.38, a P/E/G ratio of 3.74 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the prior year, the firm earned $5.31 earnings per share. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s dividend payout ratio is currently 70.84%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Mizuho raised their price target on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft increased their price objective on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Citigroup boosted their price objective on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Finally, UBS Group upped their target price on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, January 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $354.00.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.